CKD hotspots around the world: Where, why and what the lessons are. A CKJ review series

Clinical Kidney Journal

Volumn 7, Issue 6, 2014, Pages

  Martín Cleary, Catalina ^a   Ortiz, Alberto ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

aristolochic acid; Balkan nephropathy; Chinese herbs; epidemiology; genetics; Mesoamerican nephropathy

Indexed keywords

AUSTRALIAN ABORIGINE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE HOTSPOTS; ENVIRONMENTAL FACTOR; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCIENTIST; SOCIOECONOMICS;

EID: 84928388031     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu118     Document Type: Review

References (41)

1. Ortiz A, Covic A, Fliser D et al. Board of the EURECA-mWorking Group of ERA-EDTA. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831-1843
2. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128
3. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-457
4. Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223
5. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One 2013; 8: e72860
6. http://www.healthmetricsandevaluation.org/gbd/visualizations/gbd-arrow-diagram(30 July 2013, date last accessed)
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: 1-150
8. http://www.usrds.org/2011/pdf/v2-ch01-11.pdf (20 November 2013, date last accessed)
9. HoyW. Kidney Disease in Aboriginal Australians: a perspective from the Northern Territory. Clin Kidney J 2014; 7: 524-530
10. Gökmen MR, Cosyns JP, Arlt VM et al. The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 2013; 158: 469-477
11. Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis 2014; 63: 506-520
12. Vanherweghem J-L, Depierreux M, Tielemans C et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-391
13. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
14. Grollman AP, Shibutani S, Moriya M et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007; 104: 12129-12134
15. http://www.usrds.org/2010/pdf/V2-02.pdf (20 November 2013, date last accessed)
16. Freedman BI, Soucie JM, Stone SM et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999; 34: 254-258
17. Seri M, Cusano R, Gangarossa S et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 2000; 26: 103-105
18. Parsa A, Kao WH, Xie D et al.; AASK Study Investigators; CRIC Study Investigators. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl JMed 2013; 369: 2183-2196
19. Madhavan SM, O'Toole JF, Konieczkowski M et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol 2011; 22: 2119-2128
20. Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137
21. Freedman BI, Langefeld CD. The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant 2012; 27: 1288-1291
22. Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps nomore. J AmSocNephrol 2008; 19: 2047-2051
23. Cosyns JP. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf 2003; 26: 33-48
24. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543
25. Grollman AP. Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013; 54: 1-7.
26. Shaohua Z, Ananda S, Ruxia Y et al. Fatal renal failure due to the Chinese herb 'GuanMu Tong' (Aristolochia manshuriensis): autopsy findings and review of literature. Forensic Sci Int 2010; 199: e5-e7
27. http://www.agenciadenoticias.unal.edu.co/nc/ndetalle/pag/5/article/aristolochia-the-forbidden-flower.html (12 October 2013, date last accessed)
28. O'Donnell JK, Tobey M, Weiner DE et al. Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrol Dial Transplant 2011; 26: 2798-2805
29. Torres C, Aragón A, González M et al. Decreased kidney function of unknown cause in Nicaragua: a community-based survey. Am J Kidney Dis 2010; 55: 485-496
30. Wijkström J, Leiva R, Elinder CG et al. Clinical and pathological characterization of Mesoamerican nephropathy: a new kidney disease in Central America. Am J Kidney Dis 2013; 62: 908-918
31. Raines N, González M, Wyatt C et al. Risk factors for reduced glomerular filtration rate in a Nicaraguan community affected by Mesoamerican nephropathy. MEDICC Rev. 2014; 16: 16-22
32. http://www.who.int/healthinfo/global-burden-disease/estimates-country/en/index.html (12 October 2014, date last accessed)
33. Johnson RJ, Sánchez-Lozada LG. Chronic kidney disease: Mesoamerican nephropathy - new clues to the cause. Nat Rev Nephrol 2013; 9: 560-561
34. Wesseling C, Crowe J, Hogstedt C et al. First International Research Workshop on the Mesoamerican Nephropathy. Resolving the enigma of the mesoamerican nephropathy: a research workshop summary. Am J Kidney Dis 2014; 63: 396-404
35. Roncal Jimenez CA, Ishimoto T, Lanaspa MA et al. Fructokinase activity mediates dehydration-induced renal injury. Kidney Int 2014; 86: 294-302
36. Justo P, Sanz AB, Egido J et al. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54: 2424-2429
37. Sanchez-Niño MD, Poveda J, Sanz AB et al. 3,4-DGE is cytotoxic and decreases HSP27/HSPB1 in podocytes. Arch Toxicol 2014; 88: 597-608
38. Gensberger S, Mittelmaier S, Glomb MA et al. Identification and quantification of six major dicarbonyl process contaminants in high-fructose corn syrup. Anal Bioanal Chem. 2012; 403: 2923-2931
39. Torres VE, Chapman AB, Devuyst O et al. TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407-2418
40. Wanigasuriya K. Update on uncertain etiology of chronic kidney disease in Sri Lanka's north-central dry zone. MEDICC Rev 2014; 16: 61-65
41. Jayatilake N, Mendis S, Maheepala P et al. on behalf of the CKDu National Research Project Team. Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. BMC Nephrol 2013; 14: 180